- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06469684
A Health Education Intervention Tailored for Malay-Muslim Women
A Culturally-responsive Health Communication Intervention for Malay-Muslim Women on Breast Cancer Screening
The goal of this experimental study is to compare mammogram rate and knowledge in healthy women of Malay ethnicity in Singapore. The main questions it aims to answer are:
- Will health promotion intervention in the mosque on breast cancer and mammogram lead to mammogram uptake?
- Will health promotion intervention in the mosque on breast cancer and mammogram lead to change in knowledge and perception related to mammogram uptake? Participants will attend an education session in the mosque on breast cancer and mammogram by religious teacher and healthcare professional and will be given an opportunity to voluntarily sign up for mammogram on the Mammobus which will be deployed to the mosque.
Researchers will compare with healthy women of Malay ethnicity attending education session in the mosque on healthy lifestyle to see if there is a difference in mammogram uptake, and in knowledge and perception towards breast cancer and mammogram.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be a cluster randomized controlled trial of mosques to evaluate the impact of the education intervention. Each mosque is a cluster and intervention will be administered on a cluster level. We constructed a sampling frame of 29 large residential mosques out of the 70 mosques in Singapore. We excluded non-residential mosques and small mosques as these mosques do not conduct religious classes. From this sampling frame, we selected all 12 mosques that fulfilled the following eligibility criteria: i) a distance of at least 3.0 km from each other, to reduce bias of contamination, ii) availability of a parking space or an open area nearby for the MammoBus, and iii) high proportion of female mosque attendees as indicated by the Islamic Religious Council of Singapore (MUIS) which oversees the mosques in Singapore. We invited 12 mosques and received agreement from 6 mosques (clusters) for this trial. We stratified the mosques into 3 major housing estate regions (i.e. west, central and north), for stratified block randomization. Two mosques within each block or region were randomized by an independent researcher who is not on the study team, to the intervention arm and control arm (allocation ratio 1:1) using the ralloc package of STATA statistical software. Allocation will not be concealed. Three mosques on the intervention arm will receive the intervention package on breast cancer screening and three mosques on the control arm will receive an intervention package on healthy lifestyle. A total of 660 women will be recruited for the study by the research team on mosque grounds. All data collection is estimated to complete in 8 months.
Participants in the intervention arm will have three research visits and one optional research visit, therefore four research visits in total. Participants in the control arm will have three research visits in total. In both arms, all research visits will be conducted on mosque grounds. Mosque officers will allot time at the start or end of religious classes attended by potential participants to the research team to explain on the research study. Interested participants may approach interviewer in the mosque to sign up for the study. During recruitment, interviewer will go through the Participant Information Sheet and obtain verbal Informed Consent before conducting a baseline questionnaire. Only participants from the intervention arm will be asked for consent to be re-contacted for recruitment for a future study, a focus group discussion as the future study is not applicable for the control arm. Participant will be able to choose to attend one of the two available education sessions that will be held in the mosque over the next two weeks. Participant will be given a participant card to help them keep track of the dates of the session. The education session will be the second research visit for both arms. The third research visit is a voluntary session for those in the intervention arm, where participants may take part in a mammogram screening session in the mosque. The final research visit for both arms, fourth and third for intervention and control arm respectively, will take place between 2 months (± 1 month is applicable) from the recruitment, where a post-intervention survey will be carried out in the mosque. During this final research visit, participants that consented to be re-contacted for recruitment of a future follow-up study will be invited to participate in the follow-up study which is a focus group discussion.
Intervention package - i) Breast Cancer Screening: Participant will be required to complete a baseline questionnaire (10-15 minutes) upon recruitment and consent. Following recruitment, participant will be required to attend a group-level education session on breast cancer screening in the Malay language. This education session will last for an hour: 25 minutes education session by religious leaders on health-promoting Islamic teachings specifically on punitive religious beliefs, 10 minutes video on positive screening experience and breast cancer journey by breast cancer survivors, and 25 minutes question and answer on breast cancer by Malay-speaking health care provider. Participants will be asked to complete a short feedback form on the session. Participant will be given an educational pamphlet to reinforce health messages from the session and will be invited to attend a mammogram screening on the MammoBus. Participant may approach interviewers to sign up for the mammogram or register through the QR Code available on the participant card. This mammogram screening is voluntary and will be carried out in a MammoBus that will be deployed to the mosque in the following 2 weeks. The mammogram service is outsourced to National Healthcare Group Diagnostics (NHGD), that manages the MammoBus. The research team will only be involved in organising the mammogram appointments. Mammogram screening is a standard procedure in Singapore. In this research, mammogram screening will be according to the standard procedures and will be conducted by the trained radiographers from NHGD. Including waiting time and registration, this session should last for approximately 1 hour. Cost of mammogram screening will be borne by participants, where applicable. NHGD will inform participants of the results via mail when available. The research team and NUS as a whole will not have access to the mammogram results of the participants. At follow-up, 2 months (± 1 month is applicable) from the recruitment, participant will be required to answer a post-intervention questionnaire (10-15 minutes) which will be similar as the baseline survey, to measure changes in perception.
ii) Healthy lifestyle: Participant will be required to complete a baseline survey (10-15 minutes) upon recruitment and consent. Next, the participant will attend a group-level education session on healthy lifestyle in the Malay language. This education session will last for an hour - 30 minutes education session by religious leaders on health-promoting Islamic teachings, and 30 minutes question and answer on healthy lifestyle by Malay-speaking health care provider. Participants will be asked to complete a short feedback form on the session. At follow-up, 2 months (± 1 month is applicable) from the recruitment, participant will be required to answer a post-intervention questionnaire (10-15 minutes) which will be similar as the baseline questionnaire, to measure changes in perception.
Questionnaire and data collection - All data collected through questionnaires (pre-intervention questionnaire, feedback form and post-intervention questionnaire) will be linked via a unique code which will be given to the participant at recruitment and only this code will be used on all data. A separate encrypted file containing personal data of participants (i.e. phone number, name) linked to their unique code will be available only to the study administrator who is managing the service operations (i.e.arranging follow-up sessions and sending text reminders) of the study. A separate encrypted file containing personal data of participants that choose to go for mammogram (i.e. name, NRIC, phone number, address and date of birth) will be available only to the study administrator who is managing the mammogram appointments. Upon completion of all follow-up, recruitment for the follow-up study or completion of the mammogram appointment, whichever later, the files will be deleted therefore irreversibly de-identifying the data.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 117549
- National University of Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Identifying as Malay-Muslim woman
- Aged 50-69
- Citizens or permanent residents of Singapore
- No history of breast cancer
- Had not gone for mammogram screening in the last 2 years
Exclusion Criteria:
- No basic fluency in the Malay language
- Not able to provide a coherent response
- Declined photography of the education session
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
This arm receive health promotion intervention on breast cancer and mammogram including Mammobus deployment.
|
1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
|
|
Placebo Comparator: Control
This arm receive health promotion intervention on healthy lifestyle.
|
1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence Rate Ratio of Mammogram Uptake by Arm
Time Frame: 2-3 months
|
Attending mammogram after health education session
|
2-3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence Rate Ratio of Knowledge and Perception at Follow-up by Arm, adjusting for baseline
Time Frame: 2-3 months
|
Survey output on knowledge and perception on health behaviour, breast cancer and mammogram
|
2-3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUS-IRB-2022-662
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Health education session
-
Universidad de BurgosFundación Instituto Valenciano de Oncología; Fundación Trinidad AlfonsoCompletedBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIIASpain
-
Abant Izzet Baysal UniversityCompleted
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedCervical CancerUnited States
-
MEE Productions, Inc.Thomas Jefferson UniversityCompletedHuman Papilloma VirusUnited States
-
Polytechnic Institute of PortoAveiro UniversityUnknownRespiratory Tract InfectionsPortugal
-
NYU Langone HealthNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Chang Gung Memorial HospitalNot yet recruitingCommunicationTaiwan
-
Wake Forest University Health SciencesCompleted
-
Temple UniversityNational Cancer Institute (NCI)Completed
-
Simon GregsonNational Institute of Mental Health (NIMH); University of Copenhagen; London... and other collaboratorsCompleted